- Home
- SF vs ICLR Comparison
SF vs ICLR Comparison
Compare SF & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SF
- ICLR
- Stock Information
- Founded
- SF 1890
- ICLR 1990
- Country
- SF United States
- ICLR Ireland
- Employees
- SF N/A
- ICLR N/A
- Industry
- SF Investment Bankers/Brokers/Service
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- Sector
- SF Finance
- ICLR Health Care
- Exchange
- SF Nasdaq
- ICLR Nasdaq
- Market Cap
- SF 9.8B
- ICLR 11.6B
- IPO Year
- SF N/A
- ICLR 1998
- Fundamental
- Price
- SF $109.92
- ICLR $143.54
- Analyst Decision
- SF Hold
- ICLR Buy
- Analyst Count
- SF 9
- ICLR 12
- Target Price
- SF $112.38
- ICLR $187.82
- AVG Volume (30 Days)
- SF 741.0K
- ICLR 1.2M
- Earning Date
- SF 07-28-2025
- ICLR 07-23-2025
- Dividend Yield
- SF 1.68%
- ICLR N/A
- EPS Growth
- SF 19.51
- ICLR 11.53
- EPS
- SF 5.24
- ICLR 9.19
- Revenue
- SF $5,030,597,000.00
- ICLR $8,192,621,999.00
- Revenue This Year
- SF $8.07
- ICLR N/A
- Revenue Next Year
- SF $10.55
- ICLR $1.69
- P/E Ratio
- SF $20.94
- ICLR $15.98
- Revenue Growth
- SF 14.86
- ICLR N/A
- 52 Week Low
- SF $73.27
- ICLR $125.10
- 52 Week High
- SF $120.64
- ICLR $342.55
- Technical
- Relative Strength Index (RSI)
- SF 66.76
- ICLR 45.87
- Support Level
- SF $106.10
- ICLR $142.16
- Resistance Level
- SF $110.90
- ICLR $153.62
- Average True Range (ATR)
- SF 2.32
- ICLR 5.51
- MACD
- SF -0.07
- ICLR -0.91
- Stochastic Oscillator
- SF 84.83
- ICLR 10.04
About SF Stifel Financial Corporation
Stifel Financial is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 67% of the company's net revenue is derived from its global wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.